US02290A1025 - ADR
11.2 +0.3 (+2.75%)
After market: 11.2 0 (0%)
AMBRX BIOPHARMA INC-ADR
NASDAQ:AMAM (9/28/2023, 7:00:00 PM)After market: 11.2 0 (0%)
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Ambrx Biopharma Inc. operates as a clinical-stage biologics company. The company is headquartered in La Jolla, California and currently employs 66 full-time employees. The company went IPO on 2021-06-18. The company is focused on discovering and developing a novel class of engineered precision biologics, using its expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids (SAAs), into proteins within living cells. Its product candidates are designed to overcome the inherent limitations of conventional conjugation approaches that use natural amino acids for non-site-specific conjugation, offering potential safety and benefits to treat patients across multiple therapeutic areas. Its SAA incorporation technology is designed to develop a range of product candidate modality, such as antibody-drug conjugates (ADCs), immuno-oncology conjugate, bispecific antibodies, PEGylated peptides, modified cytokines and immuno-stimulating antibody conjugates. Its lead ADC product candidates in clinical development: ARX788 and ARX517. ARX517 is an anti-prostate-specific membrane antigen.
AMBRX BIOPHARMA INC-ADR
10975 North Torrey Pines Road
La Jolla CALIFORNIA
CEO: Feng Tian
In-person event and virtual webcast to be held on Sunday, October 22, 2023 at 8:00pm CEST / 2:00pm ET...
A big buy by an asset manager spurred interest in the biotech stock.
Ambrx Biopharma (AMAM) disclosed on Sept. 19 that Coronation Asset Management purchased 2.15M shares in the company from a period between Sept.15 to 18. The shares were purchased at a...
SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., Ambrx (or the “Company”) (NASDAQ: AMAM), today announced that Daniel J. O’Connor,...
The company has another update on its prostate cancer program that could further prod shares.
Here you can normally see the latest stock twits on AMAM, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.